Lilly(US:LLY)2024-04-30 16:04Revenue and Income Growth - Revenue for the three months ended March 31, 2024, was $8,768.0 million, a 26% increase from $6,960.0 million in the same period of 2023[111]. - Net income rose to $2,242.9 million, reflecting a 67% increase compared to $1,344.9 million in the prior year[111]. - Diluted earnings per share increased to $2.48, up 66% from $1.49 in the same quarter of 2023[111]. - U.S. revenue increased by 28% to $5,694.4 million, driven by strong demand for Zepbound, Mounjaro, and Verzenio, despite a decrease in Trulicity[131]. - Outside the U.S., revenue rose by 22% to $3,073.7 million, primarily due to increased volume from Mounjaro, Verzenio, Jardiance, and Tyvyt[131]. - Revenue of Mounjaro in the U.S. was $1.52 billion for the three months ended March 31, 2024, up from $536.4 million in the same period in 2023, reflecting higher realized prices and increased demand[133]. - Trulicity revenue decreased by 30% in the U.S. during the same period, primarily due to supply constraints and competitive dynamics[133]. - Verzenio revenue increased by 38% in the U.S. and 42% outside the U.S. during the three months ended March 31, 2024, driven by increased demand[133]. Product Development and Regulatory Approvals - Approximately 50 new medicine candidates are currently in clinical development or under regulatory review, with several in late-stage trials[113]. - Empagliflozin (Jardiance) received regulatory approval in the U.S. and EU in 2023, and in Japan in 2024 for chronic kidney disease and obesity indications[114]. - Tirzepatide (Mounjaro, Zepbound) is undergoing Phase 3 trials for obesity and obstructive sleep apnea, with recent announcements indicating successful primary endpoint results[114]. Market and Pricing Pressures - The increase in revenue was primarily driven by higher sales of Mounjaro, Zepbound, Verzenio, and Jardiance, despite a decline in Trulicity sales[111]. - The Inflation Reduction Act of 2022 may lead to significant pricing pressures, with Jardiance selected for government-set prices effective in 2026[120]. - The company anticipates additional significant products will be selected for government pricing, potentially accelerating revenue erosion prior to exclusivity expirations[120]. - The IRA's provisions are expected to significantly influence business strategies, particularly affecting investment attractiveness in small molecule innovation[122]. Operational Challenges - Demand for incretin medicines continues to exceed production capacity, leading to wholesaler backorders and tight supply expected to persist[123]. - The company is expanding manufacturing capacity and exploring different delivery methods for tirzepatide to meet demand[123]. - Increased research and development expenses, along with marketing and administrative costs, partially offset the gains in net income and earnings per share[111]. - Regulatory scrutiny and potential changes in tax laws may adversely impact future consolidated results and cash flows[125][126]. - Foreign currency exchange rate fluctuations pose a risk to consolidated results, particularly against the euro, Japanese yen, and Chinese yuan[127]. - Ongoing litigation and investigations related to pricing and access issues could negatively impact business operations and results[122]. Financial Position - Gross margin for the three months ended March 31, 2024, was $7.09 billion, representing 80.9% of revenue, an increase from 76.6% in the same period in 2023[136]. - Research and development expenses increased by 27% to $2.52 billion, driven by higher development expenses for late-stage assets[136]. - Total debt increased to $26.21 billion as of March 31, 2024, up by $986.1 million from $25.23 billion as of December 31, 2023[138]. - Cash and cash equivalents decreased to $2.46 billion as of March 31, 2024, compared to $2.82 billion as of December 31, 2023[138]. - The company anticipates funding a proposed acquisition of a manufacturing facility in Wisconsin primarily through cash on hand and the issuance of commercial paper[138]. - The effective tax rate for the three months ended March 31, 2024, was 11.6%, down from 12.1% in the same period in 2023[136]. - The company has $7.42 billion of unused committed bank credit facilities, with $7.00 billion available to support its commercial paper program[138].